Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

• ClinicalTrials.gov Identifier: NCT03527147
• Recruitment Status: Completed
• First Posted: May 17, 2018
• Last Update Posted: August 15, 2022
• Sponsor: Acerta Pharma BV
• Collaborator: AstraZeneca
• Information provided by (Responsible Party): Acerta Pharma BV

Study Description

Brief Summary:

This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).

Condition or disease	Intervention/treatment	Phase
NHL; DLBCL; Non-hodgkin's Lymphoma; Diffuse Large B Cell Lymphoma	Drug: AZD9150; Drug: Acalabrutinib; Drug: AZD6738; Drug: Hu5F9-G4; Drug: Rituximab; Drug: AZD5153	Phase 1

Detailed Description:

This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's lymphoma (NHL). Each study arm will be conducted in a predefined disease subset. All study arms are open label and allocation to each study arm will not be randomized.

As this master platform protocol has multiple study arms, subjects can be screened for several study arms at once. Likewise, a subject who ends participation in one study arm may be rescreened for participation in another (separate) study arm.

The primary objective of the study is to evaluate the safety of targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL). This protocol has a modular design, with the potential for future treatment arms to be added via protocol amendment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 30 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
• Actual Study Start Date: June 19, 2018
• Actual Primary Completion Date: March 31, 2021
• Actual Study Completion Date: March 31, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: AZD9150 + Acalabrutinib; AZD9150 given in combination with acalabrutinib	Drug: AZD9150; AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).; Other Name: STAT3 inhibitor; Drug: Acalabrutinib; Acalabrutinib will be administered orally twice daily (bid).; Other Names: CALQUENCE®; ACP-196
Experimental: AZD6738 + Acalabrutinib; AZD6738 in combination with acalabrutinib	Drug: Acalabrutinib; Acalabrutinib will be administered orally twice daily (bid).; Other Names: CALQUENCE®; ACP-196; Drug: AZD6738; AZD6738 will be administered orally twice daily (bid).; Other Name: ATR inhibitor
Experimental: Hu5F9-G4 + rituximab + Acalabrutinib; Hu5F9-G4/rituximab in combination with acalabrutinib	Drug: Acalabrutinib; Acalabrutinib will be administered orally twice daily (bid).; Other Names: CALQUENCE®; ACP-196; Drug: Hu5F9-G4; HU5F9-G4 infusions will be given on Weekly (Day 1, 8, 15, and 22) during the first two 28-day cycles, then will be given every two weeks (Day 1 and Day 15) in Cycle 3 and beyond.; Other Name: anti-CD47 antibody; Drug: Rituximab; Rituximab infusions will be given Weekly starting on Day 8 (Day 8, 15, and 22) during the first 28-day cycle (4 weeks), then Day 1 of each 4 week cycle for Cycles 2-6. Starting with Cycle 8, Rituximab will be infused on Day 1 of every other cycle (every 8 weeks).; Other Name: RITUXAN®
Experimental: AZD5153 + Acalabrutinib; AZD5153 in combination with acalabrutinib	Drug: Acalabrutinib; Acalabrutinib will be administered orally twice daily (bid).; Other Names: CALQUENCE®; ACP-196; Drug: AZD5153; AZD5153 will be administered orally once per day (qd).; Other Name: BRD4 inhibitor

Outcome Measures

Primary Outcome Measures :

1. Safety of the study treatments when given in combination [Incidence of adverse events] [ Time Frame: Through to study completion, an average of 1 year ]
   Incidence of adverse events

Secondary Outcome Measures :

1. Assessment of the efficacy of each treatment by evaluation of overall response rate using RECIL 2017 response criteria [ Time Frame: Through to study completion, an average of 1 year ]
   The overall response rate (ORR) is defined as the rate of subjects who achieve either a partial response (PR) or complete response (CR) as assessed by investigators before receiving any other anticancer therapy.
2. Duration of response (DOR) using RECIL 2017 response criteria for the anti-tumour activity of each therapy. [ Time Frame: Through to study completion, an average of 1 year ]
   Duration of Response (DOR) is defined as the time from the first objective response of CR or PR to the time of documented disease progression or death due to any cause, whichever occurs first.
3. Progression free survival (PFS) using RECIL 2017 response criteria for the anti-tumour activity of each therapy. [ Time Frame: Through to study completion, an average of 1 year ]
   Progression free survival (PFS) is defined as the time from first dose date to documented objective disease progression, or death from any cause, whichever occurs first. Disease progression will be determined by the investigators per standard response criteria as outlined in each respective study arm.
4. Overall Survival (OS) [ Time Frame: From the beginning of treatment until the date of death from any cause, assessed up to 12 months ]
   Overall Survival (OS) is defined as the time from first dose until the date of death from any cause.
5. Peak plasma concentration (Cmax) of Study Drug A (Arm 1) [ Time Frame: Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only; then predose and approximately 1 hr (end of infusion of Study Drug A) on Day 1 of every odd cycle starting with Cycle 3 through study completion, an average of 1 year ]
6. Peak plasma concentration (Cmax) of Study Drug B (Arm 2) [ Time Frame: Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1 ]
7. Area under the plasma concentration versus time curve (AUC) of Study Drug A (Arm 1) [ Time Frame: Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only; then predose and approximately 1 hr (end of infusion of Study Drug A) on Day 1 of every odd cycle starting with Cycle 3 through study completion, an average of 1 year ]
8. Area under the plasma concentration versus time curve (AUC) of Study Drug B (Arm 2) [ Time Frame: Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1 ]
9. Presence of Anti-Drug Antibody (ADA) titres in subjects treated with Study Drug A [ Time Frame: Samples will be collected predose on Days 1 and 8 of Cycle 1 and predose on Day 1 of every odd cycle starting with Cycle 3 ]
10. Peak plasma concentration (Cmax) of acalabrutinib (Arm 1) [ Time Frame: Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only ]
11. Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 1) [ Time Frame: Samples will be collected predose and 1, 4, 6 hours postdose on Cycle 1 Day 8 only ]
12. Peak plasma concentration (Cmax) of acalabrutinib (Arm 2) [ Time Frame: Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1 ]
13. Area under the plasma concentration versus time curve (AUC) for acalabrutinib (Arm 2) [ Time Frame: Samples will be collected predose and 1, 4, 8 hours postdose on Cycle 1 Day 8 only; then predose on Cycle 2 Day 1 and Cycle 3 Day 1 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 130 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Inclusion Criteria For All Arms:

1. Diagnosis of relapsed/refractory aggressive Non Hodgkin's Lymphoma (NHL) with histology based on established World Health Organization (WHO) criteria.
2. Must have received ≥1 prior line of therapy for the treatment of current histology, there are no known curative treatment options available, or subject ineligible for potential curative options.
3. Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy. Not applicable for cutaneous lesions.
4. ECOG performance status of ≤2.

Inclusion Criteria for Arm 1:

1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 2:

1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T-cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 3:

1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Inclusion Criteria for Arm 4:

1. Must have previously received rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate, and prednisone or equivalent regimen with stem-cell rescue. Or who are ineligible for highdose chemotherapy with stem-cell rescue and/or chimeric antigen receptor (CAR) T cell therapy.

Ineligibility for high-dose therapy with stem cell rescue and/or CAR T-cell therapy will be determined by the investigator.

Exclusion Criteria:

Exclusion Criteria For All Arms:

1. History of prior malignancy except for the following: a) Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening and felt to be at low risk for recurrence by treating physician, b) Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled nonmelanomatous skin cancer, c) Adequately treated carcinoma in situ without current evidence of disease, d) Evidence of severe or uncontrolled systemic disease, or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses or uncontrolled active systemic fungal, bacterial, viral, or other infection, or intravenous anti-infective treatment within 2 weeks before first dose of study treatment.
2. Serologic status reflecting active hepatitis B or C infection.
3. Prior use of standard antilymphoma therapy or radiation therapy within 14 days of receiving the first dose of study treatment (not including palliative radiotherapy or palliative corticosteroid use).
4. Requires ongoing immunosuppressive therapy, including systemic corticosteroids for treatment of lymphoid cancer or other conditions.
5. For subjects under DLT review only: Any haematopoietic growth factors or darbepoetin within 14 days of the first dose of study treatment.

Exclusion Criteria for Arm 1:

1. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.
2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
3. Requires treatment with proton-pump inhibitors.
4. Requires treatment with strong CYP3A inhibitors or inducers.

Exclusion Criteria for Arm 2:

1. Relative hypotension (< 90/60 mm Hg) or clinically relevant orthostatic hypotension, including a fall in blood pressure of >20 mm Hg.
2. Uncontrolled hypertension requiring clinical intervention.
3. At risk for brain perfusion problems based on medical history.
4. Mean resting QT interval (QTc) calculated using Fridericia's formula (QTcF) >470 msec for female subjects and >450 msec for male subjects obtained from 3 electrocardiograms (ECGs), or congenital long QT syndrome.
5. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.
6. Known to have tested positive for human immunodeficiency virus (HIV) & requires treatment with restricted medications.
7. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
8. Requires treatment with proton-pump inhibitors.

Exclusion Criteria for Arm 3:

1. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.
2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
3. Requires treatment with proton-pump inhibitors.
4. Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of RBC transfusions during the 4-week period prior to screening.
5. History of haemolytic anaemia or Evans syndrome in the last 3 months before enrolment.
6. Positive IgG component of the direct antiglobulin test (DAT).
7. Prior treatment with CD47 or SIRPα-targeting agents.
8. Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab

Exclusion Criteria for Arm 4:

1. Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.
2. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
3. Requires treatment with proton-pump inhibitors.
4. Requires treatment with CYP3A inhibitors or inducers or substrates of drug transporters.
5. History of tuberculosis.
6. Mean resting corrected QT interval (QTcF) >450 msec obtained from 3 electrocardiograms (ECGs); clinically important ECG findings, or risk factors for QTc prolongation.
7. Subjects receiving antiplatelet or anticoagulant therapies within 28 days of first dose of study drug.

Contacts and Locations

Locations

United States, California

Research Site

Los Angeles, California, United States, 90095

United States, Florida

Research Site

Sarasota, Florida, United States, 34232

United States, Georgia

Research Site

Atlanta, Georgia, United States, 30322

United States, Louisiana

Research Site

New Orleans, Louisiana, United States, 70112

United States, Maryland

Research Site

Bethesda, Maryland, United States, 20892

United States, Nebraska

Research Site

Omaha, Nebraska, United States, 68198

United States, New York

Research Site

Rochester, New York, United States, 14642

United States, Tennessee

Research Site

Nashville, Tennessee, United States, 37203

United States, Virginia

Research Site

Charlottesville, Virginia, United States, 22908

United States, Washington

Research Site

Seattle, Washington, United States, 98104

United Kingdom

Research Site

London, United Kingdom, W1G 6AD

Research Site

Oxford, United Kingdom, OX3 7EJ

Sponsors and Collaborators

Acerta Pharma BV

AstraZeneca

Investigators

• Study Chair: Ian Flinn, MD, PhD; Tennessee Oncology

More Information

Additional Information:

Related Info 

Results of this clinical trial are available on www.astrazenecaclinicaltrials.com 

• Responsible Party: Acerta Pharma BV
• ClinicalTrials.gov Identifier: NCT03527147
• Other Study ID Numbers: ACE-LY-111; 2017-004191-63 ( EudraCT Number ); D9820C00001 ( Other Identifier: AstraZeneca ); LYM 138 ( Other Identifier: Sarah Cannon Development Innovations )
• First Posted: May 17, 2018
• Last Update Posted: August 15, 2022
• Last Verified: August 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Acerta Pharma BV:

Acalabrutinib; CALQUENCE®; ACP-196; Platform study; Master protocol; PRISM; Hu-5F9; Rituximab; ATR; STAT3; Anti-CD47; BRD4

Additional relevant MeSH terms:

Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, B-Cell; Rituximab; Magrolimab; Acalabrutinib; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Tyrosine Kinase Inhibitors; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action